All In Biotech

Drug Trial Radar · NCT00922714

Scandinavian Intensive Care Unit (ICU) Glutamine Study

Glutamine to Intensive Care Patients - a Prospective, Double-Blind, Placebo-Controlled Multicenter Study in the Scandinavian Countries

Last checked: Nov 19, 2026Latest source record: Jun 17, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedPivotal-lookingRandomized with 1,000 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,000

Planned (sponsor's estimate)

Start

Oct 2003

Primary completion

May 2007

Study completion Aug 2009

Sponsor

Lead sponsor
Scandinavian Critical Care Trials GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 17, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Single group
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective double-blinded placebo-controlled block randomized study in intensive care patients comparing intravenous glutamine supplementation to placebo. The hypothesis is an improvement of clinical outcome. The primary endpoint is a reduction in the Sequential Organ Failure Assessment (SOFA) score on day 7 of treatment.

Conditions

  • ICU Patients

Interventions

  • GlutamineDrug

    Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)

  • saline (placebo)Drug

    NaCl 0.9 g/L

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. A reduction in SOFA-scoreTime frame: Day 7 of treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Intensive Care Unit, Karolinska University Hospital Huddinge

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.